Disease relevance of ACRBP

• Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen [1].
• In normal tissues, OY-TES-1 mRNA was expressed only in testis, whereas in malignant tissues, a variable proportion of a wide array of cancers, including bladder, breast, lung, liver, and colon cancers, expressed OY-TES-1 [1].
• OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer [2].
• Two MAbs in group C, SP24 and SP32, cross-reacted with vaccinia, cowpox, ectromelia, and rabbit fibroma viruses [3].

High impact information on ACRBP

• OY-TES-1 maps to chromosome 12p12-p13 and contains 10 exons [1].
• Southern blot analysis suggests the presence of two OY-TES-1-related genes in the human genome [1].
• Inhibin-alpha and the spermatocyte marker acrosin-binding protein were significantly lower in the CTD but not CT groups, compared with controls, but did not differ between treated groups [4].
• Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy [2].
• Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen [2].

Anatomical context of ACRBP

• Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative [2].
• OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues [2].
• Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells [5].

Analytical, diagnostic and therapeutic context of ACRBP

• These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC [2].
• Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors [2].
• Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA [2].

References